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Travmatik Beyin Hasarı olan Acil Servis Hastalarında Sonucu Öngörme 
Aracı Olarak Serum S100B Protein 
SUMMARY
Objectives
Traumatic brain injury is a common cause of death and disability world-
wide. Early recognition of patients with brain cellular damage allows 
for early rehabilitation and patient outcome improvement.
Methods
In this prospective study, the clinical conditions of patients with mild to 
moderate traumatic brain injury (TBI) were assessed, and patient serum 
S100B levels were measured. Patients were followed up one month 
later and evaluated for level of consciousness, presence or absence of 
post-traumatic headache, and daily activity performance (using the 
Barthel scale). Student’s t-test and the chi-square test were used for 
data analysis, which was performed using SPSS software.
Results
The mean serum S100B value was significantly lower for patients with 
minor TBI than for patients with moderate TBI (23.1±14.2 ng/dl and 
134.0±245.0 ng/dl, respectively). Patients with normal CT scans also 
had statistically significantly lower serum S100B levels than patients 
with abnormal CT findings. The mean S100B value was statistically 
significantly higher for patients with suspected diffused axonal injury 
(632.18±516.1 ng/dl) than for patients with other abnormal CT find-
ings (p=0.000): 24.97±22.9 ng/dl in patients with normal CT results; 
41.56±25.7 ng/dl in patients with skull bone fracture; 57.38 ±28.9 ng/
dl in patients with intracranial hemorrhage; and 76.23±38.3 ng/dl in 
patients with fracture plus intracranial hemorrhage).
Conclusions
Serum S100B levels increase in patients with minor to moderate TBIs, 
especially in those with diffused axonal injury. However, serum S100B 
values cannot accurately predict one-month neuropsychological out-
comes and performance.
Key words: Biomarker; head trauma; S100B protein; traumatic brain in-
jury.
ÖZET
Amaç
Travmatik beyin travması dünya ölçeğinde olağan bir ölüm ve özürlülük 
nedenidir. Beyin hücre hasarı olan hastaların erkenden tanınması erkend-
sen rehabilitasyon ve hasta sonuçlarında iyileşmeye olanak tanır.
Gereç ve Yöntem
Bu prospektif çalışmada hafif-orta derecede travmatik beyin hasarı (TBH) 
olan hastaların klinik durumları değerlendirildi ve hastaların serum S100B 
düzeyleri ölçüldü. Hastalar bir ay sonra takip edildi, bilinç düzeyleri, trav-
ma sonrası baş ağrısı olup olmaması ve günlük aktivite performansı (Bart-
hel ölçeğini kullanarak) açısından değerlendirildi. Veri analizinde SPSS 
yazılımı ile Student t-testi ve ki-kare testi kullanıldı.
Bulgular
Orta derecede TBH geçirmiş olanlara göre hafif derecede TBH geçirmiş 
hastalarda ortalama serum S100B değeri anlamlı derecede daha düşük-
tü (sırasıyla, 134,0±245,0 ng/dl ve 23,1±14,2 ng/dl). BT taramaları normal 
olmayan hastalara göre normal olanlarda serum S100B düzeyleri istatis-
tiksel açıdan anlamlı derece daha düşüktü. Ortalama S100B değeri yaygın 
akson hasarından kuşkulanılan hastalarda (632,18±516,1 ng/dl) başka 
anormal BT bulguları olan hastalardan anlamlı derecede daha düşük idi 
(p=0.000). Normal BT sonuçları olan hastalarda, 24.97±22.9 ng/dl; kafa-
tası kemiği kırıkları olanlarda 41.56±25.7 ng/dl; intrakraniyal kanaması 
olanlarda 57.38±28.9 ng/dl, kırıkla birlikte intrakraniyal kanaması olan-
larda 76.23±38.3 ng/dl.
Sonuç
Hafif ve orta derecede TBH özellikle yaygın akson travması olanlarda se-
rum S100B düzeyleri yükselmektedir. Ancak serum S100B değerleri 1 ay 
sonrasının nöropsikolojik sonuçları ve performansını  doğru biçimde  ön-
görememektedir.
Anahtar sözcükler: Biyobelirteç; kafa travması; S100B proteini; travmatik be-
yin hasarı.
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Introduction
Traumatic brain injury (TBI) is a common cause of death and 
disability worldwide. TBI is a public health priority because it 
is associated with extensive physical, psychological and social 
impacts and a high economic burden.[1] Some studies have 
demonstrated that more than 10-40% of patients with TBI are 
still disabled 6-12 months after trauma, including those with 
mild TBI and unremarkable neuroimaging findings. Although 
early recognition and proper management of patients with 
TBI may result in better rehabilitation and substantial out-
come improvement, assessing different cellular and clinical 
aspects and effects of TBI is still less than optimal.[2-4] 
S100B, a calcium binding protein highly expressed in as-
troglial cells of the brain and released in cerebrospinal fluid 
(CSF) and blood, can be measured by available immunoas-
say kits. Different studies have evaluated S100B as a bio-
marker for different brain injuries, such as stroke[5,6], bacte-
rial meningitis[7], carbon monoxide poisoning[8] and TBI[9-12]. 
Some recent studies have also highlighted the complex re-
lease pattern of S100B and its potential role in brain tissue 
repair processes[13-17]
This prospective study evaluates the diagnostic and prog-
nostic roles of serum S100B protein in emergency depart-
ment (ED) patients with minor to moderate TBI.
Materials and Methods 
Patients were enrolled conveniently between March and 
May 2012 at two teaching hospitals with a total annual cen-
sus of 80,000 adult patients. The institutional ethics commit-
tee (Faculty of Medicine, Iran University of Medical Sciences) 
approved this prospective study, and informed consent was 
obtained from all patients. 
Participants
Patients at least 18 years old with a clinical diagnosis of acute 
mild to moderate TBI were enrolled. Patients with a history 
of isolated head trauma and Glasgow Coma Scale (GCS) 
score between 9 and 15 who presented in the ED within the 
first six hours of their head injury were considered to have 
mild to moderate TBI. All clinical assessments, including GCS 
calculations, were performed by a research assistant who 
was a physician. The research assistant was blinded to other 
assessments results. 
Patients with the following were excluded: severe TBI 
(GCS≤8); hemodynamic instability; body temperature great-
er than 38.5°C; concurrent trauma to any other organs; con-
current primary and secondary brain injury, including refrac-
tory severe hypoxia (arterial oxygen saturation <92% while 
receiving 100% oxygen), post-traumatic seizure, and skull 
bone fracture; and any other identified or suspected dif-
ferential diagnosis for the patient’s decreased level of con-
sciousness, including alcohol abuse, drug abuse, substance 
abuse, drug toxicity, hypo/hyperglycemia, hypo/hypernatre-
mia, endocrine disorder, or infection. Patients who did not 
undergo a head CT scan were also excluded. 
Intervention
S100B assay: A blood sample was drawn from the peripheral 
veins within the first six hours of ED admission. The time of 
blood sample collection was recorded. Samples were centri-
fuged, and the serum was refrigerated at -20°C until analyzed.
Neuroimaging: Ten millimeter thick slices obtained using a 
GE VCT Lightspeed 64 multi-slice detector were interpreted 
by a board certified radiologist and confirmed by another 
consultant radiologist who was blinded to the first inter-
pretation. Both radiologists were blinded to the clinical 
conditions and S100B results of the patients. All pathologic 
findings, including skull bone fracture and any type of intra-
cranial hemorrhage (e.g. brain contusion, subdural/epidural 
intracranial hematoma), were reported as positive comput-
ed tomography findings. 
Follow up: The patients were called by two blinded research 
assistant one month later. During follow-up, patients were 
evaluated for level of consciousness, presence or absence of 
post-traumatic headaches, and daily activity performance 
(using the Barthel scale) to determine if any significant in-
tracranial complications had occurred (.i.e. complications 
requiring further neuroimaging).
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Figure 1. Participant flow over the course of the study.
Subjects Assessed for Eligibility 
(n=187)
Included patients (n=109)
Excluded Patients (n=78):
- Inclusion criteria not met (n=21)
 - hemodynamic instability (6)
 - concurrent trauma to other
 organs (18)
 - concurrent brain injuries (34)
 - other causes of decreased level
 of consciousness (20)
Lost to follow-up (n=19)
- Wasted blood samples (11)
- Refused to participate (6)
- Failed to reach by telephone (2)
Measurements
Initial TBI severity was assessed using the GCS. Patients with 
GCS scores between 9 and 15 were considered to have mild 
to moderate TBI. To measure S100B serum levels, the human 
S100 ELISA kit (BioVendor - laboratorni medicina a.s., Brno, 
Czech Republic) was used. The lowest detection limit of the 
test is about 15 pg/ml. Serum S100B levels were measured 
in ng/dl.
The Barthel scale is an ordinal 10-variable scale used to mea-
sure patient performance on daily activities and to predict 
the likelihood a patient will be able to live at home indepen-
dently. The Barthel scale has high inter-rater and test re-test 
reliability, as well as, high correlations with other measures 
of physical disability. The ten Barthel scale variables are: 
presence/absence of fecal incontinence; presence/absence 
of urinary incontinence; and help needed with grooming, 
toilet use, feeding, transfers, walking, dressing, climbing 
stairs, and bathing. Each variable is given a score (between 
0 and 3). These scores are summed to determine the total 
score (out of 20). The higher the Barthel score, the less as-
sistance the patient is likely to need with daily activities after 
discharge from the hospital. For example, when a person can 
perform about 50% of their daily tasks and activities inde-
pendently, then their Barthel score will be 10 out of 20.[18-20] 
Patient outcome measures were level of consciousness, re-
sidual headache, and Barthel score one month after trauma. 
Data Analysis
The Student’s t-test was used to compare the mean values 
of quantitative variables, and the Chi square test was used 
to compare qualitative variables. All data analyses were per-
formed with SPSS version 13.5 (SPSS, Inc., Chicago, IL).
Results
One hundred eighty-seven patients were assessed for eli-
gibility, and 78 patients were excluded from the study: six 
patients had hemodynamic instability; 18 patients had 
concurrent trauma to other organs; 34 patients had concur-
rent brain injuries; and 20 patients had other causes of de-
creased level of consciousness. Venous blood samples were 
obtained from 109 patients with minor to moderate TBI who 
had undergone CT as a part of their routine diagnostic eval-
uations. Eleven samples were wasted due to various errors 
between initial preparation and analysis. A total of 98 pa-
tients with mild to moderate TBI and available serum S100B 
results were followed. During the telephone follow-up one 
month post-trauma, six patients refused to continue partici-
pating in the study, and two additional cases were unreach-
able by telephone. Follow-up interviews were performed for 
90 patients, all of whom completed the study. No patients 
had died in the month between injury and follow-up, and all 
patients had GCS scores of 15.
The mean age of the study participants was 33.1±10.3 years 
(95% CI: 29.99-34.28) and ranged from 18 to 50 years old. 
Other basic characteristics of the patients are shown in Ta-
ble1. In the present study, 38 (80.9%) of the minor TBI pa-
tients and 6 (14.0%) of the moderate TBI patients had normal 
CT results. Suspected diffused axonal injury (DAI) was not 
seen in the minor TBI patients, but 5 (11.6%) of the moder-
ate TBI patients had suspected DAI. GCS scores were signifi-
cantly different between the patients with normal CT results 
and the patients with abnormal CT findings (p=0.000). The 
mean serum S100B value was 23.1±14.2 ng/dl (95% CI: 17.4-
27.3) in patients with minor TBI and 134.0±245.0 ng/dl (95% 
CI 51.1-179.6) in patients with moderate TBI. Student’s t-test 
demonstrated that the difference was statistically significant 
(p=0.003). The mean serum S100B value was statistically sig-
nificantly higher in patients with suspected DAI compared 
to patients with other abnormal CT findings (p=0.000). Se-
rum S100B results are summarized in Table 2.
Initial GCS scores, CT findings, headache, and Barthel scores 
of patients with Barthel scores ≤18 and with the highest 
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Table 1. Basic characteristics of study participants
Variable n %
Sex
 Male 80 88.9
 Female 10 11.1
Initial GCS
 15  40 44.4
 14  7 7.8
 13  13 14.4
 12  19 21.1
 11  6 6.7
 10  5 5.6
Mechanism of injury
 Auto-Pedestrian 36 40.0
 MVC 23 25.6
 Falling 16 17.8
 Direct trauma 9 10.0
 Others 6 6.7
CT findings
 Normal 44 48.9
 DAI 5 5.6
 ICH 10 11.1
 Fx  10 11.1
 Fx+ICH 21 23.3
S100B levels are shown in Table 3. At one-month follow-up, 
3 (3.3%) patients had Barthel scores less than 18, 12 (13.4%) 
had Barthel scores of 18 or 19, and 75 (83.3%) had Barthel 
scores of 20. The mean serum S100B value was 206.43±316.0 
ng/dl (95% CI: 49.3-163.4) in patients with Barthel scores less 
than 18 (range: 68-1047 ng/dl). Patients with Barthel scores 
of 18 and 19 had a mean serum S100B level of 88.20±46.5 
ng/dl (95% CI: 24.8-407.8, range: 48-175 ng/dl). The mean 
serum S100B level was 59.51±156.9 ng/dl (95% CI: 18.6-99.6) 
for patients with Barthel scores of 20 (range: 68-1047 ng/dl). 
Serum S100B levels were higher in patients with lower Bar-
thel scores, but the difference was not statistically significant 
(p=0.06). 
Thirty-eight (42.2%) patients had residual headaches 
one month after TBI. The mean serum S100B level was 
87.03±163.2 ng/dl (95% CI: 26.5-150.6) in patients with 
residual headaches, and 68.13±188.5 ng/dl (95% CI: 11.3-
127.8) in patients without headaches; the difference was not 
statistically significant (p=0.59).
Discussion
The S100B protein has a half-life of two hours and can be 
measured both in CSF and in the blood. Although some 
studies have shown that S100B protein levels increase after 
extra-cranial injuries in the absence of brain injury,[21] many 
other studies have introduced S100B protein as a highly sen-
sitive and speciﬁc biomarker of CNS injuries.[13-17] S100B has 
been suggested as a triage tool for identifying patients who 
need neuroimaging and as a diagnostic tool for early recog-
nition of patients with possible brain tissue injury and timely 
administration of medication (e.g. benzodiazepines to re-
duce post-concussion syndrome risk after mild TBI). S100B 
has also been suggested as a prognostic tool to identify at-
risk patients and to begin rehabilitation activities as soon as 
possible, especially for patients who do not need neurosur-
gical interventions.[22-26]
The present study found that although serum S100B increas-
es in minor to moderate traumatic brain injuries (especially 
in cases of DAI), it cannot accurately predict one-month out-
comes. These results are compatible with some other stud-
ies which have emphasized the complicated release pattern 
of S100B. These past studies have highlighted the role of 
blood-brain barrier integrity and disruption in S100B release 
into the serum, the poor correlation between serum and CSF 
S100B levels, and the possible reparative roles of S100B that 
may improve outcomes in patients with acute brain injuries. 
These studies also mention that the relationship between 
S100B values and likely outcomes in patients with TBI is not 
necessarily a causative relationship.[27]
A study of a large cohort of patients showed some associa-
tion between high serum S100B level and poor outcome 
in patients with brain injury, but not significant enough to 
support use as an outcome prediction tool.[28] Similarly, a re-
view by Townend showed that, although patients with high 
serum S100B levels at initial evaluation may be at higher risk 
for disability after TBI, no association between serum S100B 
levels and the neuro-psychological performance of injured 
patients has been established.[2] Metting et al. studied 94 pa-
tients with mild TBI and demonstrated that S100B is not re-
lated to outcome or imaging results.[29] Some newer studies 
have proposed that serum S100B level might be used for pre-
dicting the probability of brain death in patients with TBI.[30]
Conclusion
The current study showed that serum S100B levels increase 
with minor to moderate TBIs, especially in patients with sus-
pected DAI. However, serum S100B cannot accurately pre-
dict one-month neuropsychological outcomes and perfor-
mance.
Limitations
The present study has some limitations. The study was con-
ducted at two teaching hospitals, and the human S-100 
ELISA kits may not be available at other smaller hospitals. 
Only patients who had undergone brain CT were enrolled; 
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Table 2. Serum S100B levels in patients with different CT results
CT Findings Mean±SD* (ng/dl) 95% Confidence Interval 
Skull Fracture 41.56±25.7 22.1-58.9
ICH† 5.38±28.9 28.9
Skull Fracture plus ICH 76.23±38.3 57.7-92.7
DAI†† 632.18±516.1 -9.7-1272.0
Abnormal 125.0±238.5 53.1-194.8
Normal 24.9±22.9 16.9-30.9
†: Intracranial hemorrhage; ††: Diffused axonal injury; *: Standard deviation.
patients who had not undergone CT or who refused to un-
dergo neuroimaging were not included. The sample size was 
small, and similar studies with larger sample sizes would be 
preferable. The study did not focus on any cutoff S100B level 
to categorize at-risk patients, though it might be helpful to 
determine a cutoff diagnostic serum S100B value.
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